CON: Treatment Intensification in Poor Prognosis Germ Cell Tumors

Video

In this video, Dr. Bosl argues against treatment intensification for poor-prognosis germ cell tumor patients who display unfavorable marker decline.

In this video, George J. Bosl, MD, of Memorial Sloan Kettering Cancer Center, New York, argues against treatment intensification for poor-prognosis germ cell tumor patients who display unfavorable marker decline.

Bosl gave a presentation on this topic earlier this year at the 2017 Genitourinary Cancers Symposium in Orlando, Florida.

Recent Videos
Related Content
Evaluation and Management of Testicular Cancer After Late Relapse

Evaluation and Management of Testicular Cancer After Late Relapse

Joanna L. Langner, MS;Frederick Millard, MD;Vera Vavinskaya, MD;Haiyan Zhang, MD;Nuphat Yodkhunnatham, MD;Aditya Bagrodia, MD
April 16th 2024
Article

The clinical quandary by Langer et al discusses a contralateral late relapse of the original right nonseminomatous germ cell tumors.

Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies

Treatment of Castration-Resistant Prostate Cancer: Current Options and Novel Therapies

Andrew J. Armstrong, MD, MSc;Tomasz M. Beer, MD
April 27th 2012
Podcast

Two experts discuss newly available and upcoming treatment options, such as abiraterone and MDV3100, for patients with castration-resistant prostate cancer.

Treatment with retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy is associated with low long-term morbidity.

RPLND May Reduce Need for Chemo/Radiation for Testicular Seminoma

Russ Conroy
March 24th 2023
Article

Treatment with retroperitoneal lymph node dissection for testicular seminoma with limited retroperitoneal lymphadenopathy is associated with low long-term morbidity.

Targeted Therapies: A Paradigm Shift in RCC

Targeted Therapies: A Paradigm Shift in RCC

Robert J. Motzer, MD
June 8th 2010
Podcast

Listen to internationally regarded oncologist and clinical investigator, Robert J. Motzer, MD, attending physician at Memorial Sloan-Kettering Cancer Center, discuss the past, present, and future trends in renal cell carcinoma.

Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor

Management of Residual Disease After First-line Chemotherapy in a Patient With a Nonseminomatous Germ Cell Tumor

Regina Barragan-Carrillo, MD;Samantha Mateos-Corella, MD;Carlos Ortiz-Hidalgo, MD;Eva A Izquierdo-Echavarri, MD;Ricardo Castillejos-Molina, MD;Martín Angel;Ignacio Barragan-Arteaga;Thomas W. Flaig, MD;María T. Bourlon, MD, MSc, FASCO
December 17th 2021
Article

In this edition of Clinical Quandaries, Regina Barragan-Carrillo, MD, and colleagues present a case of an 18-year-old man who has a 1-month history of nonpainful right testicular enlargement.

Treatment with Cisplatin-Based Chemotherapy Yields High Risk of Mortality Unrelated to Disease in Testicular Cancer

Treatment with Cisplatin-Based Chemotherapy Yields High Risk of Mortality Unrelated to Disease in Testicular Cancer

Ariana Pelosci
September 29th 2021
Article

Patients with testicular cancer who are treated with platinum-based chemotherapy or radiotherapy have an increased risk of mortality unrealted to their disease.